SpringerProtocols: Abstract: Design of Prodrugs for Suicide Gene Therapy

Design of Prodrugs for Suicide Gene Therapy

By: Dan Niculescu-Duvaz², Ion Niculescu-Duvaz², Caroline J. Springer²

Abstract

Full Text

Download PDF (372K)

A major problem for cancer treatment is the presence of toxic side effects associated with chemotherapeutic agents that limit their efficacy. Alternatively, this can be regarded as the limitation of the dose of drug available to a patient before major general toxicity occurs, with consequent decrease in tumor cell killing and reduced chances of cure. A novel approach designed to circumvent this problem and increase the local concentration of cytotoxic drug at the tumor site with fewer and less drastic systemic side effects is gene-directed enzyme prodrug therapy (GDEPT).

Affiliation(s): (2) Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK

Book Title: Suicide Gene Therapy: Methods and Reviews

Series: Methods in Molecular Medicine | Volume: 90 | Pub. Date: Nov-04-2003 | Page Range: 161-202 | DOI: 10.1385/1-59259-429-8:161

Subject: Genetics/Genomics

References

Download References

1.	Greco, O., Folkes, L. K., Wardman, P., Tozer, G. M., and Dachs, G. U. (2000) Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish per-oxidase/indole-3-acetic acid. Cancer Gene Ther. 7, 1414–1420.

2.	Prospective, open-label, parallel-group, randomized multicenter trial comparing the efficiency of surgery, radiation, and injection of murine cells producing herpes simplex virus thymidine kinase vector followed by intravenous ganciclovir against the efficacy of surgery and radiation in the treatment of newly diagnosed, previously untreated glioblastoma, NIH OBA Human Gene Transfer Clinical Trials Database/NIH protocol number: 157-(1996-08) Available at http://www4.od.nih.gov/oba/rac/clinicaltrial.

3.	Connors, T. A. (1995) The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702–709.

4.	Springer, C. J. and Niculescu-Duvaz, I. (1996) Gene directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv. Drug Deliv. Rev. 22, 351–364.

5.	Niculescu-Duvaz, I., Spooner, R. A., Marais, R., and Springer, C. J. S. (1998) Gene-directed enzyme prodrug therapy. Bioconjug. Chem. 9, 4–22.

6.	Melton, R., Connors, T., and Knox, R. J. (1999) The use of prodrugs in targeted anticancer therapies. S. T. P. Pharm. Sci. 9, 13–33.

7.	Springer, C. J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Investig. 105, 1161–1167.

8.	Xu, G. and McLeod, H. L. (2001) Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7, 3314–3324.

9.	Denny, W. A. (2001) Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577–595.

10.	Greco, O. and Dachs, G. U. (2001) Gene directed enzyme/prodrug therapy of cancer: Hystorical appraisal and future prospectives. J. Cell. Physiol. 187, 22–36.

11.	Chen, L., Waxman, D. J., Chen, D., and Kufe, D. C. (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56, 1331–1340.

12.	Marais, R., Spooner, R. A., Stribbling, S. M., Light, Y., Martin, J., and Springer, C. J. S. (1997) A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnol. 15, 1373–1377.

13.	Kojima, A., Hackett, N. R., Ohwada, A., and Crystal, R. G. (1998) In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Investig. 101, 1789–1796.

14.	McCart, J. A., Puhlmann, M., Lee, J., et al. (2000) Complex interaction between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7, 1217–1223.

15.	Griffiths, L., Binley, K., Iqball, S., et al. (2000) The macrophage—a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7, 255–262.

16.	Denny, W. A. and Wilson, W. R. (1998) The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J. Pharm. Pharmacol. 50, 387–394.

17.	Niculescu-Duvaz, I., Baracu, I., and Balaban, A. T. (1990) Alkylating agents, in Chemistry of Antitumour Agents. Wilman, D. E. V., ed., Blackie & Son: London, pp. 63–130.

18.	Secrist, J. A. III, Parker, W. B., Allan, P. W., et al. (1999) Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18, 745–757.

19.	Denny, W. A. (1996) The design of selectively-activated prodrugs for cancer chemotherapy. Curr. Pharm. Des. 2, 281–294.

20.	Springer, C. J., Dowell, R. L., Burke, P. J., et al. (1995) Optimization of alkylating prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J. Med. Chem. 38, 5051–5065.

21.	Denny, W. and Wilson, W. R. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastases Rev. 12, 135–151.

22.	Siim, B. G., Denny, W. A., and Wilson, W. R. (1997) Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 9, 357–369.

23.	Patterson, L. H. and Raleigh, S. M. (1998) Reductive Metabolism: Its Application in Prodrug Activation, IOS, 1998.

24.	Jaffar, M., Williams, K. J., and Stratford, I. J. (2001) Bioreductive and gene therapy approaches to hypoxic diseases. Adv. Drug Deliv. Rev. 53, 217–228.

25.	Bagshawe, K. D., Springer, C. J., Searle, F., et al. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700–703.

26.	Niculescu-Duvaz, I. and Springer, C. J. (1995) Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr. Med. Chem. 2, 687–706.

27.	Satchi, R., Connors, T. A., and Duncan, R. (2001) PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070–1076.

28.	Hamstra, D. A., Page, M., Maybaum, J., and Rehemtulla, A. (2000) Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-α-peptide prodrugs. Cancer Res. 60, 657–665.

29.	Heine, D., Muller, R., and Brusselbach, S. (2001) Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther. 8, 1005–1010.

30.	Weyel, D., Sedlacek, H.-H., Muller, R., and Brusselbach, S. (2000) Secreted human β-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7, 224–231.

31.	Spooner, R. A., Maycroft, K. A., Paterson, H., Friedlos, F., Springer, C. J., and Marais, R. (2001) Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. Int. J. Cancer 93, 123–130.

32.	Alrabiah, F. A. and Sacks, S. L. (1996) New antiherpesvirus agents—their targets and therapeutic potential. Drugs 52, 17–32.

33.	Marley, J. (1997) Antiviral therapy in herpes zoster: a review. Antiviral Chem. Chemoth. 8 (Suppl. 1), 37–42.

34.	Maudgal, P. C. and Declerq, E. (1991) Bromovinyldeoxyuridine treatment of herpetic-keratitis clinically resistant to other antiviral agents. Curr. Eye Res. 10 (Suppl. S), 193–199.

35.	Averett, D. R., Koszalka, G. W., Fyfe, J. A., Roberts, G. B., Purifoy, D. J. M., and Krenitsky, T. A. (1991) 6-Methoxypurine arabinoside as a selective and potent inhibitor of Varicella-Zoster virus. Antimicrob. Agents Chemother. 35, 851–857.

36.	Ishiguro, K., Taira, S., Sasaki, T., and Nariuchi, H. (1988) Depletion of Mycoplasma from infected cell lines by limiting dilution in 6-methylpurine deoxyriboside. J. Immunol. Methods 108, 39–43.

37.	Besnard, C., Monthioux, E., and Jami, J. (1987) Selection against expression of the Escherichia Coli gene gpt in hrpt+ mouse teratocarcinoma and hybrid cells. Mol. Cell Biol. 7, 4139–4141.

38.	Marr, J. J. (1991) Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med. 118, 111–119.

39.	Ghannoum, M. A. and Rice, L. B. (1999) Antifungal agents: mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12, 501.

40.	Kondo, K., Sakamoto, J., Nakazato, H., et al. (2000) A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer. Oncol. Rep. 7, 485–490.

41.	Cheson, B. D. and Simon, R. (1987) Low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes—a review of 20 years experience. Semin. Oncol. 14 (Suppl. 1), 126–133.

42.	Colvin, O. M. (1999) An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 5, 555–560.

43.	Franck, R. W. and Tomasz, M. (1990) The chemistry of mitomycins, in Wilman, D. E. W., ed., Chemistry of Antitumor Agents, Blackie & Son Ltd., London and Glasgow, pp. 379–394.

44.	Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S. S., Seeber, S., and Rustum, Y. M. (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19, 1501–1518.

45.	Grant, S. C., Kris, M. G., Young, C. W., and Sirotnak, F. M. (1993) Edatrexate, an antifolate with antitumor activity—a review. Cancer Invest. 11, 36–45.

46.	Lee, D. J., Trotti, A., Spencer, S., et al. (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int. J. Radiat. Oncol. Biol. Phys. 42, 811–815.

47.	Nakamuro, K., Okuno, T., and Hasegawa, T. (2000) Metabolism of selenoamino acids and contribution of selenium methylation to their toxicity. J. Health Sci. 46, 418–421.

48.	Wolf, C. R., Statham, C. N., McMenamin, M. G., et al. (1982) The relationship between the catalytic activities of rabbit pulmonary cytochrome P-450 isozymes and the lung-specific toxicity of the furan derivative, 4-ipomeanol. Mol. Pharmacol. 22, 738–744.

49.	Ellard, S. and Parry, J. M. (1993) A comparative study of the use of primary chinese-hamster liver cultures and genetically-engineered immortal V79 chinese-hamster cell-lines expressing rat liver CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays. Toxicology 82, 131–149.

50.	Roberts, J. J., Friedlos, F., and Knox, R. J. (1986) CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 140, 1073–1078.

51.	Folkes, L. K. and Wardman, P. (2001) Oxidative activation of indole-3-acetic acids to cytotoxic species—a potential new role for plant auxins in cancer therapy. Biochem. Pharmacol. 61, 129–136.

52.	Miner, D. J. and Kissinger, P. T. (1979) Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem. Pharmacol. 28, 3285–3290.

53.	De Clercq, E., Andrei G., De Bolle, L., et al. (2001) Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids 20, 271–285.

54.	Friedlos, F., Denny, W. A., Palmer, B. D., and Springer, C. J. (1997) Mustard prodrug for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. 40, 1270–1275.

55.	Niculescu-Duvaz, D., Niculescu-Duvaz, I., Friedlos, F. F., et al. (1998) Self-immolative mustard prodrugs for suicide gene therapy. J. Med. Chem. 41, 5297–5309.

56.	Niculescu-Duvaz, I., Niculescu-Duvaz, D., Friedlos, F., et al. (1999) Self-immolative anthracycline prodrugs for suicide gene therapy. J. Med. Chem. 42, 2485–2489.

57.	Ghosh, A. K., Khan, S., Marini, F., Nelson, J. A., and Farquhar, D. (2000) A daunorubicin β-galactoside prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Tetrahedron Lett. 41, 4871–4874.

58.	Hayes, G. M., Carpenito, C., Davis, P. D., Dougherty, S. T., Dirks, J. F., and Dougherty, G. J. (2002) Alternative splicing as a novel means of regulating the expression of therapeutic genes. Cancer Gene Ther. 9, 133–141.

59.	Simonova, M., Wall, A., Weissleder, R., and Bogdanov, A. J. (2000) Tyrosinase mutants are capable of prodrug activation in transfected nonmelanomic cells. Cancer Res. 60, 6656–6662.

60.	Marais, R., Spooner, R. A., Light, Y., Martin, J., and Springer, C. J. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56, 4735–4742.

61.	Friedlos, F., Davies, L., Scanlon, S., et al. (2002) Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 62, 1724–1729.

62.	Hamstra, D. A. and Rehemtulla, A. (1999) Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum. Gene Ther. 10, 235–248.

63.	Hay, M. P., Wilson, W. R., and Denny, W. A. (1999) Nitrobenzyl carbamate prodrugs of enediyenes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg. Med. Chem. Lett. 9, 3417–3422.

64.	Hay, M. P., Sykes, B. M., Denny, W. A., and Wilson, W. R. (1999) A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 9, 2237–2242.

65.	Sagnou, M. J., Howard, P. W., Gregson, S. J., Eno-Amooquaye, E., Burke, P. J., and Thurston, D. E. (2000) Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 10, 2083–2086.

66.	Grove, J. I., Searle, P. F., Weedon, S. J., Green, N. K., McNeish, I. A., and Kerr, D. J. (1999) Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Des. 14, 461–472.

67.	Alena, F., Jimbow, K., and Ito, S. (1990) Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo. Cancer Res. 50, 3743–3747.

68.	Riley, P. A., Cooksey, C. J., Johnson, C. I., Land, E. J., Latter, A. M., and Ramsden, C. A. (1997) Melanogenesis-targeted anti-melanoma pro-drug development: effect of side chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur. J. Cancer 33, 135–143.

69.	Tando, M., Thomas, P. D., Shokravi, M., et al. (1998) Synthesis and antitumor effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol. Biochem. Pharmacol. 55, 2023–2029.

70.	Jordan, A. M., Khan, T. H., Osborn, H. M. I., Photiou, A., and Riley, P. A. (1999) Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma. Bioorg. Med. Chem. 7, 1775–1780.

71.	Jordan, A. M., Khan, T. H., Malkin, H., Osborn, H. M. I., Photiou, A., and Riley, P. A. (2001) Melanocyte-directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma. Bioorg. Med. Chem. 9, 1549–1558.

72.	Rauth, A. M., Melo, T., and Misra, V. (1998) Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42, 755–762.

73.	Springer, C. J. and Niculescu-Duvaz, I. (2002) Gene-directed enzyme prodrug therapy, in Anticancer Drug Development (Baguley, B. C. and Kerr, D. J., eds.), Academic, San Diego, CA.

74.	Cortes, M. L., de Felipe, P., Martin, V., Hughes, M. A., and Izquierdo, M. (1998) Succesful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 5, 1499–1507.

75.	Aghi, M., Kramm, C. M., and Breakefield, X. O. (1999) Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J. Natl. Cancer Inst. 91, 1233–1241.

76.	Aghi, M., Hochberg, F., and Breakfield, X. O. (2000) Prodrug activation enzymes in cancer gene therapy. J. Gene Med. 2, 148–164.

77.	Springer, C. J., Antoniw, P., Bagshave, K. D., Searle, F., Bisset, G. M., and Jarman, M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33, 677–681.

78.	Smith, G. K., Banks, S., Blumenkopf, T. A., et al. (1997) Towards antibody directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem. 272, 15,804–15,816.

79.	Dowell, R., Springer, C. J., Davies, D. H., et al. (1996) New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternative to the amide link. J. Med. Chem. 39, 1100–1105.

80.	Wierdl, M., Morton, C. L., Weeks, J. K., Danks, M. K., Harris, L. C., and Potter, P. M. (2001) Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 61, 5078–5082.

81.	Senter, P. D., Saulnier, M. G., Schreiber, G. J., et al. (1988) Antitumor effects of antibody alkaline-phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842–4846.

82.	Haisma, H. J., Boven, E., Vanmuijen, M., Dejong, J., Vandervijgh, W. J. F., and Pinedo, H. M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474–478.

83.	Roffler, S. R., Wang, S. M., Chern, J. W., Yeh, M. Y., and Tung, E. (1991) Antineoplastic glucuronide prodrug treatment of human tumor-cells targeted with a monoclonal-antibody enzyme conjugate. Biochem. Pharmacol. 42, 2062–2065.

84.	Azoulay, M., Florent, J.-C., Monneret, C., et al. (1995) Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti-Cancer Drug Des. 10, 441–450.

85.	Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. (1994) Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302–8306.

86.	Whartenby, K. A., Darnowski, J. W., Scott, M. F., and Calabresi, P. (2002) A role for MAP kinase in the antitumor activity of a nucleoside analog. Cancer Gene Ther. 9, 37–43.

87.	Krohne, T. U., Shankara, S., Geissler, M., et al. (2001) Mechanism of cell death induced by suicide genes encoding purine nucleoside phosphorylase in human hepatocellular carcinoma cells in vitro. Hepatology 34, 511–518.

88.	Akyurek, L. M., Nallamshetty, S., Aoki, K., Yang, Z.-Y., Nabel, G. J., and Nabel, E. G. (2001) Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular cell proliferation in vivo. Mol. Ther. 3, 779–786.

89.	Jounaidi, Y. and Waxman, D. J. (2000) Combination of the bioreductive drug tirapazamine with the therapeutic prodrug cyclophosphamide for P450/P450-reductase based cancer gene therapy. Cancer Res. 60, 3761–3769.

90.	Lakhanpal, S., Donehower, R. C., and Rowinsky, E. K. (2001) Phase II study of 4-ipomeanol, a naturally occuring alkylating furan, in patients with advanced hepatocellular carcinoma. Invest. New Drugs 19, 69–76.

91.	Stegman, L. D., Zheng, H., Neal, E. R., et al. (1998) Induction of cytotoxic oxidative stress by d-alanine in brain tumor cells expressing Rhodotorula Gracilis d-amino acids: a cancer gene therapy strategy. Hum. Gene Ther. 9, 185–193.

92.	Tamiya, T., Ono, Y., Wei, M. X., Mroz, P. J., Moolten, F. L., and Chiocca, E. A. (1996) Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 3, 155–162.

93.	Miki, K., Xu, M., Gupta, A., et al. (2001) Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 61, 6805–6810.

94.	Carl, P. L., Chakravaty, P. K., and Katzenellenbogen, J. A. (1981) A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479–480.

95.	Wakselman, M. (1983) 1,4-and 1,6-elimination from hydroxy-and amino-substituted benzyl systems: chemical and biochemical applications. Nouv. J. Chim. 7, 439–447.

96.	Mauger, A. B., Burke, P. J., Somani, H. H., Friedlos, F., and Knox, R. J. (1994) Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37, 3452–3458.

97.	Lee, M., Simpson, J. E., Woo, S., et al. (1997) Synthesis of an aminopropyl analog of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADH. Bioorg. Med. Chem. Lett. 7, 1065–1070.

98.	Gesson, J.-P., Jacquesy, J.-C., Mondon, M., et al. (1994) Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Des. 9, 409–423.

99.	Leenders, R. C. G., Damen, E. W. P., Bijsterveld, E. J. A., et al. (1999) Novel anthracycline-spacer-β-glucuronide,-β-glucoside, and-β-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 7, 1597–1610.

100.	Alexander, R. P., Beeley, N. R. A., O’Driscott, M., et al. (1991) Cephalosporin nitrogen mustard carbamate prodrugs for ADEPT. Tetrahedron Lett. 32, 3269–3272.

101.	Svensson, H. P., Kadow, J. F., Vrudhula, V. M., Wallace, P. M., and Senter, P. D. (1992) Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug. Chem. 3, 176–181.

102.	Meyer, D. L., Jungheim, L. N., Law, K. L., et al. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956–3963.

103.	Jungheim, L. N., Sheperd, T. A., and Kling, J. K. (1993) Synthesis of a cephalosporin-doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme. Heterocycles 35, 339–348.

104.	Hanessian, S. and Wang, J. (1993) Design and synthesis of a cephalosporin carboplatinum prodrug activatable by a beta-lactamase. Canadian J. Chem. 71, 896–906.

105.	Moore, J., Ohmstede, C., Dickerson, S., et al. (1997) Gene therapy utilizing enzymes capable of extracellular conversion of multiple prodrugs. Proc. Am. Assoc. Cancer Res. 38, 379.

106.	Sykes, B. M., Atwell, G. J., Hogg, A., Wilson, W. R., O’Connor, C. J., and Denny, W. R. (1999) N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary aminevia nitroreduction and intramolecular cyclization. J. Med. Chem. 42, 346–355.

107.	de Bont, D. B. A., Leenderens, R. G. G., Haisma, H. J., van der Meulen-Muileman, I., and Scheeren, H. W. (1997) Synthesis and biological activity of β-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorg. Med. Chem. 5, 405–414.

108.	Hay, M. P., Sykes, B. M., Denny, W. A., and O’Connor, C. J. (1999) Substituent effects on the kinetics of reductively-initiated fragmentation of nitrobenzyl carbamates designed as triggers for prodrugs. J. Chem. Soc. Perkin Transactions 1 19, 2759–2770.

109.	Andrianomenjanahary, S., Dong, X., Florent, J.-C., et al. (1992) Synthesis of novel targeted pro-prodrugs of anthracyclins potentially activated by a monoclonal antibody galactosidase conjugate. Bioorg. Med. Chem. Lett. 9, 1093.

110.	Atwell, G. J., Sykes, B. M., O’Connor, C. J., and Denny, W. A. (1994) Relationships between structure and kinetics of cyclisation of 2-aminoaryl amides: potential prodrugs of cyclisation-activated aromatic mustards. J. Med. Chem. 37, 371–380.

111.	Dillon, M. P., Cai, H., and Maag, H. (1996) Application of the “trimethyl lock” to ganciclovir, a pro-prodrug with increased oral bioavailability. Bioorg. Med. Chem. Lett. 6, 1653–1656.

112.	Wang, B., Zhang, H., and Wang, W. (1996) Chemical feasability studies of a potential coumarin-based prodrug system. Bioorg. Med. Chem. Lett. 6, 945–950.

113.	Schmidt, F., Florent, J.-C., Monneret, C., Straub, R., Czech, J., Gerken, M., and Bosslet, K. (1997) Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT): a phenol nitrogen mustard carbamate. Bioorg. Med. Chem. Lett. 7, 1071–1076.

114.	Sykes, B. M., Hay, M. P., Bohing-Herceg, D., Helsby, N. A., O’Connor, C. J., and Denny, W. A. (2000) Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates. J. Chem. Soc. Perkin Trans. 1 10, 1601–1608.

115.	Tercel, M., Wilson, R. W., Anderson, R. F., and Denny, W. A. (1996) Hypoxia selective antitumor agents. 12. Nitrobenzyl quaternary ammonium salts as bioreductive prodrugs of the alkylating agent mechloramine. J. Med. Chem. 39, 1084–1094.

116.	Desbene, S., Dufat-Trinh Van, H., Michel, S., et al. (1999) Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy. Anti-Cancer Drug Des. 14, 93–106.

117.	Toki, B. E., Cerveny, C. G., Wahl, A. F., and Senter, P. D. (2002) Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. 67, 1866–1872.

118.	Ghosh, A. K., Khan, S., and Farquhar, D. (1999) A β-galactoside phosphoramide mustard prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Chem. Commun. 24, 2527–2528.

119.	Hansch, C., Leo, A., and Hoekman, D. (1995) Exploring QSAR. Hydrophobic, Electronic and Steric Constants, American Chemical Society, Washington, DC.

120.	Springer, C. J. and Niculescu-Duvaz, I. (1995) Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Des. 10, 361–372.

121.	Degreve, B., DeClerq, E., and Balzarini, J. (1999) Bystander effect of purine nucleoside analogues in HSV-tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther. 6, 162–170.

122.	Rainov, N. G., Dobberstein, K. U., Sena-Esteves, M., et al. (1998) New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther. 9, 1261–1273.

123.	Thatcher, N. J., Edwards, R. J., Lemoine, N. R., Doehmer, J., and Davies, D. S. (2000) The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. Cancer Gene Ther. 7, 521–525.

124.	Bakina, E., Wu, Z., Rosenblum, M., and Farquhar, D. (1997) Intensely cytotoxic anthracycline prodrugs: glucuronides. J. Med. Chem. 40, 4013–4018.

125.	Grignet-Debrus, C., Cool, V., Baudson, N., Velu, T., and Calberg-Bacq, C.-M. (2000) The role of cellular-and prodrug-associated factors in the bystander effect induced by the varicella zoster and herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 7, 1456–1468.

126.	Hoganson, D. A., Batra, R. K., Olsen, J. C., and Boucher, R. C. (1996) Comparison of the effects of three different toxin genes and their level of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 56, 1315–1323.

127.	Nishihara, E., Nagayama, Y., Narimatsu, M., et al. (1998) Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res. 18, 1521–1526.

128.	Patterson, A. V. and Harris, A. L. (1999) Molecular chemotherapy for breast cancer. Drugs Aging 14, 75–90.

129.	Hu, L., Liu, B., and Hacking, D. R. (2000) 5′-[2-(2-Nitrophenyl)-2-methylpropionyl]-2′-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: synthesis, stability and reductive activation. Bioorg. Med. Chem. Lett. 10, 797–800.

130.	Frank, S., Steffens, S., Fischer, U., Tlolko, A., Rainov, N. G., and Kramm, C. M. (2002) Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. Cancer Gene Ther. 9, 178–188.

131.	Kievit, E., Bershad, E., Ng, E., et al. (1999) Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer. Cancer Res. 59, 1417–1421.

132.	Kokoris, M. S., Sabo, P., Adman, E. T., and Black, M. E. (1999) Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6, 1415–1426.

133.	Bailey, S. M., Knox, R. J., Hobbs, S. M., et al. (1996) Investigation of alternative prodrugs for use with E. coli nitroreductase in “suicide gene” approaches to cancer therapy. Gene Ther. 3, 1143–1150.

134.	de Groot, F. M. J., Loos, W. J., Koekkoek, R., et al. (2001) Elongated multiple electronic cascade and cyclization spacer systems in activatable anticancer prodrugs for enhanced drug release. J. Org. Chem. 66, 8815–8830.

135.	Bohnenstengel, F., Friedel, G., Ritter, C. A., et al. (2000) Variability of cyclophosphamide uptake into human bronchial carcinoma: consequences for local bioactivation. Cancer Chemother. Pharmacol. 45, 63–68.

136.	Ichikawa, T., Petros, W. P., Ludeman, S. M., et al. (2001) Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 61, 864–868.

137.	Huang, Z., Raychowdhury, M. K., and Waxman, D. J. (2000) Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther. 7, 1034–1042.

138.	Springer, C. J., Niculescu-Duvaz, I., and Pedley, B. R. (1994) Novel prodrugs of alkylating agents derived from 2-fluoro-and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem. 37, 2361–2370.

139.	Balzarini, J., Degreve, B., Andrei, G., et al. (1998) Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther. 5, 419–426.

140.	Mohr, L., Rainov, N. G., Mohr, U. G., and Wands, J. R. (2000) Rabbit cytochrome P450 4B1: a novel prodrug activating gene for pharmacogene therapy of hepatocellular canrcinoma. Cancer Gene Ther. 7, 1008–1014.

Comments (Loading...)

Post comment/View all comments